We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

103 hedge funds and large institutions have $150M invested in Xeris Biopharma Holdings in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

665% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $1.35M

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

56% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 25

19% more capital invested

Capital invested by funds: $126M → $150M (+$23.4M)

7% more funds holding

Funds holding: 96 → 103 (+7)

2.32% less ownership

Funds ownership: 52.37% → 50.05% (-2.3%)

Holders
103
Holders Change
+7
Holders Change %
+7.29%
% of All Funds
1.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
39
Reduced
25
Closed
12
Calls
$10.3M
Puts
$1.35M
Net Calls
+$8.96M
Net Calls Change
+$264K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$35.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$5.15M
3
TA
Tamarack Advisers
California
+$1.89M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.8M
5
Morgan Stanley
Morgan Stanley
New York
+$1.48M

Top Sellers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
-$4.07M
2
RG
Redmile Group
California
-$3.7M
3
6CM
683 Capital Management
New York
-$877K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$783K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$733K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$747K -$1.68K -311 -0.2%
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$732K +$140K +25,924 +19%
N
28
Nuveen
North Carolina
$612K -$69K -12,794 -9%
Charles Schwab
29
Charles Schwab
California
$550K +$21.9K +4,064 +3%
Citadel Advisors
30
Citadel Advisors
Florida
$487K +$266K +49,265 +84%
Deutsche Bank
31
Deutsche Bank
Germany
$451K +$350K +64,829 +185%
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$438K +$10.8K +2,000 +2%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$421K – – –
MMA
34
Miracle Mile Advisors
California
$407K -$156K -29,000 -24%
GCP
35
GSA Capital Partners
United Kingdom
$398K +$476K +88,197 New
Goldman Sachs
36
Goldman Sachs
New York
$388K -$713K -132,152 -61%
Lazard Asset Management
37
Lazard Asset Management
New York
$363K -$86.8K -16,097 -17%
Russell Investments Group
38
Russell Investments Group
United Kingdom
$350K – – –
PAM
39
Premier Asset Management
Illinois
$336K +$402K +74,515 New
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$314K – – –
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$292K – – –
Lido Advisors
42
Lido Advisors
California
$289K -$48.5K -9,000 -12%
CSS
43
Cubist Systematic Strategies
Connecticut
$275K +$84.2K +15,618 +34%
Jane Street
44
Jane Street
New York
$230K +$138K +25,495 +100%
T. Rowe Price Associates
45
T. Rowe Price Associates
Maryland
$223K +$267K +49,467 New
GIA
46
Gladstone Institutional Advisory
Florida
$219K -$16.2K -3,000 -6%
GWSG
47
GPS Wealth Strategies Group
Colorado
$212K +$5.39K +1,000 +2%
TSW
48
Thompson Siegel & Walmsley
Virginia
$203K +$236K +43,750 +3,500%
Ameriprise
49
Ameriprise
Minnesota
$197K +$182K +33,680 +336%
KSCM
50
Kamunting Street Capital Management
Florida
$192K -$6.68K -1,239 -3%
1
2
3 4 5

XERS Hedge Fund Activity: Q1 2021 in Review

103 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2021, worth a combined $150M — up 19% from $126M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new XERS positions and 12 closed out — a net gain of 7 holders — while 39 added to existing stakes and 25 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $35.3M. The largest seller was Sessa Capital, cutting an estimated $4.07M.

  • 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2021, up from 96 in Q4 2020.
  • Funds reported $150M of Xeris Biopharma Holdings stock for Q1 2021, up 19% quarter-over-quarter.
  • 19 funds opened new Xeris Biopharma Holdings positions in Q1 2021 and 12 closed out, a net change of +7 holders.
  • The largest Xeris Biopharma Holdings buyer in Q1 2021 was Deerfield Management, an estimated $35.3M added.
  • The largest Xeris Biopharma Holdings seller in Q1 2021 was Sessa Capital, an estimated $4.07M sold.

Based on aggregated 13F filings for Q1 2021.